This Biopharma Is Cleared For A Long-Term Climb

UnitedHealth (UNH) is like a Boeing 747 in a thunderstorm: big, complicated, a little bumpy right now but still very much airborne, with the engines humming stronger than most investors realize. The recent clobbering of UNH shares has more to do with short-term panic than long-term fundamentals.

If you’re in this game for quick thrills, look elsewhere. But if you’re the type who likes to accumulate cash-generating assets while the crowd hyperventilates, UnitedHealth is quietly becoming one of the best “buy the dip” plays in the healthcare sector.

Let’s be clear: 2025 was no joyride. A confluence of rising medical costs, unexpected patient utilization, and ACA policy uncertainty hit the margins like a rogue wave. The medical cost ratio surged to 89.9% in Q3 – an eyebrow-raising number, sure, but one that was within expectations and, more importantly, not expected to stick around long.

Management has their eyes on reining that back in by 2026, with 2027 already penciled in for meaningful margin expansion. Pricing will adjust, utilization will stabilize, and the company’s internal levers (read: Optum) will do the heavy lifting.

If you’re wondering whether this quarter marked the bottom, consider this: even in this “challenged” quarter, UnitedHealth still grew revenue 12.3% year-over-year to $113.2 billion, and even eked out a modest EPS beat at $2.92.

This is a company with enough earnings power to stub its toe and still jog past consensus estimates. Their own revised 2025 outlook sees adjusted EPS at $16.25, with top-line growth above 15%. Needless to say, the numbers show a company in recalibration mode.

Then there’s the quietly elegant strategic move: the final exit from Latin America. Selling Banmedica for $1 billion to a Brazilian PE firm may not be a headline-grabber, but it’s exactly the kind of housekeeping that signals discipline.

Latin America was always more of a side hustle than a core competency for UNH. By finally shutting the door on that distraction, the company tightens its focus where it matters: U.S. healthcare services, where it controls both the insurance gate and the provider supply chain through Optum. It’s a model so vertically integrated it would make Rockefeller proud.

This $1 billion isn’t just symbolic. It adds fuel to the balance sheet just in time for a $1.9 billion dividend payout in mid-December.

Management hasn’t pulled the buyback trigger recently, but don’t interpret that as a lack of confidence. It’s more about resetting debt-to-capital ratios to historical norms before reloading the cannon in 2026.

Translation: once leverage normalizes, the buybacks will likely return with a vengeance – at lower share prices, no less.

And yes, the dividend yield is now flirting with 2.7%. That may not sound like much until you realize that you’re getting paid to wait while one of the most sophisticated data-driven healthcare machines in the world realigns itself for another multiyear run.

Optum continues to print money. The backlog at Optum Insight is still a cool $25 billion. And OptumRx isn’t just filling prescriptions – it’s filling the revenue coffers. Investors too focused on headline ratios are missing the forest for the algorithmically-optimized trees.

Now, let’s address the elephant in the waiting room: politics.

Trump 2.0 healthcare reform and the ACA subsidy outlook are both up in the air. Fair enough. But UNH has always played the policy game like a chess grandmaster. They’ve been navigating these waters since HMOs were a punchline. The policy fog will lift – eventually.

In the meantime, UnitedHealth is adjusting premiums, tweaking reimbursement contracts, and doing what it’s always done best: monetizing complexity.

The truth is that Wall Street isn’t as spooked as the stock chart suggests. The big boys are watching the spread between short-term cost turbulence and long-term pricing power – and they know how this movie ends.

Earnings north of $20 per share by 2027 isn’t just plausible; it’s probable. A price target north of $400 within two years isn’t a stretch, but a glide path, assuming even modest multiple expansion.

What you’re buying here is not a perfect quarter. You’re buying world-class infrastructure, data monopolies in healthcare services, a policy-resilient business model, and the kind of fat-tail upside that makes for portfolio legends.

Sure, the stock has been dinged, but if you wait for all the lights to turn green before you act, you’ll be stuck in neutral forever.

After all, this bird wasn’t built for short hops. UNH is a long-haul machine built to reward patience and altitude. If it’s not obvious by now, let me spell it out: buy the dip.